,,ii #aahth ,,congress #b;d ,session ,s4 #edai ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,december #d1 #bjbd,mr4 ,cotton 7for himself and ,mr4 ,kaine7 introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,a ,,bill ,to require the ,secretary of ,health and ,human ,services to maintain a list of the country of origin of certain critical drugs marketed in the ,united ,states1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,protecting ,our ,essential ,medicines ,act4 #b4 ,list of critical drugs produced outside the ,united ,states ,subchapter ,a of chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cea et seq47 is amended by adding at the end the following3 #ebd;,c4 ,list of critical drugs produced outside the ,united ,states 7a7 ,list of critical drugs 7#a7 ,in general ,for purposes of strengthening the public health supply chain and industrial base1 and increasing the manufacture of essential drugs1 including biological products1 and critical inputs of such drugs in the ,united ,states1 the ,secretary shall compile and maintain a list of each drug that is-- 7,a7 approved under subsection 7c7 or 7j7 of section #eje of this ,act or licensed under subsection 7a7 or 7k7 of section #cea of the ,public ,health ,service ,act2 7,b7 imported into the ,united ,states2 and 7,c7 7i7 determined by the interagency task force established under subsection 7e7 to be critical to the health and safety of consumers in the ,united ,states2 7ii7 determined by such task force to be a drug the shortage of which would have an adverse health outcome on patients with chronic conditions2 or 7iii7 a qualified countermeasure1 as defined in section #cai;,f-#a7;a77#b7 of the ,public ,health ,service ,act1 a qualified pandemic or epidemic product1 as defined in section #cai;,f-#c7;i7 of such ,act1 or a security countermeasure1 as defined in section #cai;,f-#b7;c7 of such ,act4 7#b7 ,supply chain information ,the list required by paragraph 7#a7 shall1 with respect to each drug included on the list1 provide information about each facility registered under section #eaj that is involved in the manufacture1 preparation1 propagation1 compounding1 or processing of the drug or an ingredient of the drug4 7#c7 ,no public disclosure ,the list required by paragraph 7#a71 and any portion thereof1 shall not be publicly disclosed1 and nothing in paragraph 7#a7 or 7#b7 shall be construed as authorizing the ,secretary to disclose any information that is a trade secret or confidential information subject to section #eeb7;b77#d7 of title #e1 ,united ,states ,code1 or section #aije of title #ah1 ,united ,states ,code4 7#d7 ,permissible disclosure to national security agencies of the ,federal ,government ,the list required by paragraph 7#a7 7and any portion thereof7 may be disclosed by the ,secretary only-- 7,a7 within the ,department of ,health and ,human ,services and pursuant to reporting under subsection 7e72 and 7,b7 for purposes of evaluating supply chain vulnerabilities and other national security issues1 with national security agencies of the ,federal ,government1 including all elements of the ,department of ,defense and national intelligence agencies4 7#e7 ,definition ,in this subsection1 the term critical inputs means active pharmaceutical ingredients1 starting material for active pharmaceutical ingredients1 and other ingredients of drugs that the ,commissioner of ,food and ,drugs determines to be critical in assessing the safety and effectiveness of drugs described in paragraph 7#a74 7b7 ,additional lists 7#a7 ,in general ,in conjunction with the list under subsection 7a71 the ,secretary shall1 in consultation with the interagency task force established under subsection 7e71 compile and maintain-- 7,a7 a list of drugs included on the list under subsection 7a7 that are exclusively produced in1 or use active pharmaceutical ingredients produced in1 a foreign entity of concern 7as defined in section #iija7h7 of the ,william ,m4 7,mac7 ,thornberry ,national ,defense ,authorization ,act for ,fiscal ,year #bjba72 and 7,b7 a list identifying the top #c countries from which the ,united ,states imports drugs described in subsection 7a77#a74 7#b7 ,disclosure 7,a7 ,list of drugs 7i7 ,no public disclosure ,the list required by paragraph 7#a77;,a7 7and any portion thereof7 shall not be publicly disclosed4 7ii7 ,permissible disclosure to national security agencies of the ,federal ,government ,the list required by paragraph 7#a77;,a71 and any portion thereof1 may be disclosed by the ,secretary only-- 7,i7 within the ,department of ,health and ,human ,services1 and pursuant to reporting under subsection 7f72 and 7,,ii7 for purposes of evaluating supply chain vulnerabilities and other national security issues1 with national security agencies of the ,federal ,government4 7,b7 ,list of top #c countries ,the ,secretary shall publicly disclose the list required by paragraph 7#a77;,b71 but may not include in any such disclosure-- 7i7 information about an identifiable drug or active pharmaceutical ingredient2 or 7ii7 proprietary information regarding a drug or active pharmaceutical ingredient1 including information that is a trade secret or confidential information subject to section #eeb7;b77#d7 of title #e1 ,united ,states ,code1 or section #aije of title #ah1 ,united ,states ,code4 7c7 ,timelines 7#a7 ,initial list ,the ,secretary shall compile the initial lists of drugs under subsections 7a7 and 7b7 not later than #ahj days after the date of enactment of the ,protecting ,our ,essential ,medicines ,act4 7#b7 ,updates ,the ,secretary shall update the lists of drugs under subsections 7a7 and 7b71 as the ,secretary determines necessary and appropriate1 and not less frequently than every #b years4 7d7 ,cybersecurity measures ,prior to sharing of any lists required by subsection 7a7 or 7b71 within the ,department of ,health and ,human ,services or to national security agencies1 the ,secretary shall ensure that robust cybersecurity measures are in place to prevent inappropriate access to1 or unauthorized disclosure of1 the list or any information related to the list4 7e7 ,interagency task force 7#a7 ,establishment ,not later than #cj days after the date of enactment of the ,protecting ,our ,essential ,medicines ,act1 the ,secretary shall establish an interagency task force for purposes of identifying drugs to include in the list of critical drugs1 as described in subsection 7a77#a77;,c7 and consulting with the ,secretary with respect to compiling1 maintaining1 and updating the list under subsection 7b74 ,the task force shall be comprised of representatives of the ,federal ,government as the ,secretary1 in consultation with the ,commissioner of ,food and ,drugs1 the ,director of the ,centers for ,disease ,control and ,prevention1 the ,secretary of ,defense1 the ,assistant ,secretary for ,preparedness and ,response1 the ,secretary of ,homeland ,security1 the ,commissioner of ,u4,s4 ,customs and ,border ,protection1 and the ,director of ,national ,intelligence1 determines appropriate4 7#b7 ,procedures ,not later than #fj days after the date of enactment of the ,protecting ,our ,essential ,medicines ,act1 the task force established under paragraph 7#a7 shall submit a report on the procedures such task force will follow in making determinations with respect to drugs as described in clauses 7i7 and 7ii7 of subsection 7a77#a77;,c7 to-- 7,a7 the ,committee on ,health1 ,education1 ,labor1 and ,pensions1 the ,committee on ,finance1 and the ,committee on ,armed ,services of the ,senate2 and 7,b7 the ,committee on ,energy and ,commerce1 the ,committee on ,ways and ,means1 and the ,committee on ,armed ,services of the ,house of ,representatives4 7f7 ,reporting ,upon compiling the initial list of drugs as required under subsections 7a7 and 7b71 and upon making each update to such lists as described in subsection 7c77#b71 the ,secretary shall submit the list of drugs to-- 7#a7 the ,secretary of ,defense2 7#b7 the ,attorney ,general2 and 7#c7 the ,director of ,national ,intelligence4 4